Jubilant Pharmova Files FY26 Business Responsibility & Sustainability Report
Jubilant Pharmova Limited has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26, as required by Regulation 34 of the Listing Regulations. The report, which forms part of the Annual Report, provides comprehensive disclosures on the company's environmental, social, and governance (ESG) performance on a consolidated basis. Key business segments include Radiopharma (44.57% turnover), Contract Development and Manufacturing Organisation - Sterile Injectables (21.19%), and Contract Research, Development and Manufacturing Organisation (14.70%). The company operates 2 national and 3 international plants, serving 21 domestic and 74 international markets, with exports contributing 63.53% to its turnover. The report also details employee and worker demographics, with a total of 3786 employees and 2600 workers.
Key Highlights
- Jubilant Pharmova filed its FY26 BRSR as per listing regulations.
- Radiopharma is the largest segment, contributing 44.57% to turnover.
- Exports constitute a significant 63.53% of total turnover.
- The company operates across 2 national and 3 international locations.
- BRSR disclosures are made on a consolidated basis.
Price Impact
More from JUBLPHARMA